Franchini Massimo, Liumbruno Giancarlo Maria
Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantova, Italy.
Biologics. 2021 Feb 4;15:31-38. doi: 10.2147/BTT.S272063. eCollection 2021.
The COVID-19 pandemic in 2020 is one of the worst catastrophic events in human history. Several non-specific antiviral drugs have been tried to defeat the SARS-CoV-2, with mixed results. Convalescent plasma from patients who have recovered from COVID-19 is one of the specific biologic therapies being considered to treat SARS-CoV-2 infection. Preliminary studies have shown that convalescent plasma, containing antibodies able to neutralize SARS-CoV-2, is promising in blocking viral replication and improving patients' clinical symptoms. The results of several ongoing randomized controlled trials are, however, keenly awaited to definitively elucidate the safety and efficacy of this blood component in COVID-19. In this narrative review, we summarize the current evidence from the literature on the treatment of severe COVID-19 with convalescent plasma. A concise overview of the hypothesized mechanisms of action is also presented.
2020年的新冠疫情是人类历史上最严重的灾难性事件之一。人们尝试了多种非特异性抗病毒药物来对抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2），结果喜忧参半。新冠康复者的恢复期血浆是正在考虑用于治疗SARS-CoV-2感染的特异性生物疗法之一。初步研究表明，含有能够中和SARS-CoV-2的抗体的恢复期血浆在阻断病毒复制和改善患者临床症状方面很有前景。然而，人们急切期待着几项正在进行的随机对照试验的结果，以明确这种血液成分在新冠治疗中的安全性和有效性。在这篇叙述性综述中，我们总结了目前文献中关于使用恢复期血浆治疗重症新冠的证据。同时也简要概述了其假定的作用机制。
